Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-13.68 Insider Own0.10% Shs Outstand91.46M Perf Week9.72%
Market Cap31.25B Forward P/E- EPS next Y-11.42 Insider Trans-81.25% Shs Float63.45M Perf Month6.01%
Income-1170.50M PEG- EPS next Q-4.30 Inst Own67.90% Short Float3.39% Perf Quarter12.34%
Sales862.70M P/S36.22 EPS this Y-13.80% Inst Trans3.97% Short Ratio9.43 Perf Half Y-5.87%
Book/sh43.78 P/B7.84 EPS next Y6.60% ROA-22.30% Target Price373.74 Perf Year54.09%
Cash/sh52.84 P/C6.49 EPS next 5Y37.00% ROE-31.80% 52W Range207.96 - 388.97 Perf YTD32.78%
Dividend- P/FCF- EPS past 5Y-60.30% ROI-37.50% 52W High-11.80% Beta0.88
Dividend %- Quick Ratio4.60 Sales past 5Y103.70% Gross Margin89.70% 52W Low64.98% ATR17.21
Employees5400 Current Ratio4.60 Sales Q/Q1063.80% Oper. Margin- RSI (14)57.57 Volatility4.35% 5.52%
OptionableYes Debt/Eq0.15 EPS Q/Q114.60% Profit Margin- Rel Volume1.44 Prev Close341.45
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume227.98K Price343.09
Recom2.30 SMA207.99% SMA502.61% SMA2009.35% Volume328,796 Change0.48%
Mar-08-21Initiated China Renaissance Buy
Mar-01-21Downgrade CLSA Outperform → Underperform $330 → $321
Nov-09-20Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20Downgrade Piper Sandler Neutral → Underweight $175 → $185
Nov-06-20Downgrade Maxim Group Buy → Hold
Jul-10-20Downgrade CLSA Buy → Outperform
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Aug-03-21 09:01AM  
07:00AM  
Jul-30-21 07:43AM  
Jul-29-21 08:00PM  
Jul-28-21 03:52PM  
Jul-27-21 01:53AM  
Jul-26-21 07:00AM  
Jul-22-21 12:25PM  
Jul-09-21 06:16AM  
12:00AM  
Jul-07-21 08:00PM  
11:30AM  
Jul-01-21 07:29PM  
Jun-30-21 08:30AM  
Jun-28-21 11:31AM  
Jun-23-21 10:53AM  
12:00AM  
Jun-21-21 10:16AM  
Jun-18-21 04:30PM  
Jun-17-21 07:00AM  
Jun-11-21 10:15AM  
03:00AM  
03:00AM  
Jun-09-21 08:35AM  
07:00AM  
Jun-07-21 05:00PM  
Jun-04-21 09:00AM  
09:00AM  
Jun-01-21 10:00AM  
May-21-21 07:40AM  
07:00AM  
May-19-21 05:00PM  
07:00AM  
May-18-21 03:43AM  
May-12-21 10:00AM  
May-07-21 12:00AM  
May-06-21 04:05PM  
Apr-28-21 01:19PM  
07:00AM  
Apr-12-21 01:30PM  
08:40AM  
Apr-11-21 04:00PM  
Apr-08-21 07:00AM  
07:00AM  
Apr-07-21 07:00PM  
Mar-30-21 08:30AM  
Mar-16-21 01:20PM  
Mar-10-21 04:30PM  
07:00AM  
Mar-05-21 08:30AM  
Mar-02-21 07:00AM  
Feb-27-21 01:21AM  
Feb-26-21 07:00AM  
06:41AM  
Feb-25-21 04:05PM  
Feb-17-21 05:00PM  
09:33AM  
07:00AM  
Jan-27-21 05:45PM  
Jan-26-21 10:01PM  
Jan-23-21 01:52AM  
Jan-15-21 09:34AM  
Jan-14-21 04:35PM  
Jan-13-21 11:00PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
07:00AM  
Jan-07-21 07:00AM  
Dec-27-20 11:00PM  
Dec-14-20 09:10PM  
Dec-11-20 06:17PM  
Dec-07-20 07:00PM  
10:00AM  
Dec-06-20 12:30PM  
Dec-01-20 11:00PM  
04:15PM  
Nov-23-20 07:00AM  
Nov-20-20 07:37AM  
Nov-19-20 08:00PM  
Nov-17-20 07:00AM  
Nov-07-20 08:04AM  
Nov-05-20 04:05PM  
09:00AM  
Oct-09-20 07:05AM  
Oct-06-20 07:00AM  
Oct-01-20 12:00PM  
08:15AM  
Sep-27-20 06:12AM  
Sep-21-20 07:00AM  
Sep-17-20 06:05PM  
Sep-10-20 09:00AM  
Sep-09-20 07:00AM  
Sep-04-20 09:15AM  
Aug-27-20 08:02AM  
07:00AM  
Aug-25-20 07:00AM  
Aug-24-20 08:08AM  
Aug-07-20 12:00PM  
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OYLER JOHNChief Executive OfficerJul 22Sale71.8269,2164,971,3600Jul 22 06:23 PM
OYLER JOHNChief Executive OfficerJul 21Sale184.0927,1604,999,8230Jul 22 06:21 PM
OYLER JOHNChief Executive OfficerJul 20Sale132.2643,6955,779,0540Jul 22 06:21 PM
Huang JaneCMO, HematologyJul 15Option Exercise146.9021,0003,085,00221,000Jul 19 04:43 PM
Huang JaneCMO, HematologyJul 15Sale332.4221,0006,980,7710Jul 19 04:43 PM
OYLER JOHNChief Executive OfficerJul 08Sale93.8067,1816,301,7330Jul 08 07:11 PM
OYLER JOHNChief Executive OfficerJul 07Sale325.2330097,5700Jul 08 07:11 PM
OYLER JOHNChief Executive OfficerJul 07Sale137.5466,4469,139,022300Jul 08 07:09 PM
OYLER JOHNChief Executive OfficerJul 06Sale93.6957,3755,375,6150Jul 08 07:09 PM
Wu XiaobinPresident, COO & GM ChinaJul 06Sale325.5310,1803,313,9270Jul 08 06:25 PM
Wang Julia AijunChief Financial OfficerJul 01Sale349.06308107,5120Jul 01 04:58 PM
Liang HowardCFO & Chief Strategy OfficerJun 28Sale365.00446162,7900Jun 30 04:45 PM
Wang LaiGlobal Head of R&DJun 28Sale362.48455164,9300Jun 30 04:48 PM
Wu XiaobinPresident, COO & GM ChinaJun 18Sale330.931,156382,5510Jun 21 04:49 PM
Wang LaiGlobal Head of R&DJun 18Sale331.15802265,5830Jun 21 04:47 PM
Huang JaneCMO, HematologyJun 18Sale325.66469152,7330Jun 21 04:45 PM
Liang HowardCFO & Chief Strategy OfficerJun 18Sale325.89486158,3830Jun 21 04:43 PM
Chen Timothy Yung-ChengDirectorJun 10Option Exercise31.592,83689,5892,836Jun 11 04:36 PM
Chen Timothy Yung-ChengDirectorJun 10Sale352.032,836998,3490Jun 11 04:36 PM
Chen Timothy Yung-ChengDirectorJun 09Option Exercise31.593,16499,9513,164Jun 11 04:36 PM
Chen Timothy Yung-ChengDirectorJun 09Sale351.353,1641,111,6690Jun 11 04:36 PM
Wu XiaobinPresident, COO & GM ChinaJun 07Sale352.543,3981,197,9170Jun 09 04:49 PM
Liang HowardCFO & Chief Strategy OfficerJun 07Sale354.16650230,2030Jun 09 04:48 PM
Wang LaiGlobal Head of R&DJun 07Sale354.26656232,3920Jun 09 04:46 PM
Huang JaneCMO, HematologyJun 07Sale351.55603211,9860Jun 09 04:45 PM
Huang JaneCMO, HematologyJun 01Sale362.64540195,8280Jun 02 04:40 PM
Huang JaneCMO, HematologyMay 28Option Exercise29.491,50044,2351,500Jun 02 04:40 PM
Huang JaneCMO, HematologyMay 28Sale356.301,500534,4530Jun 02 04:40 PM
Wang XiaodongChair, Scientific Advisory BrdMay 10Option Exercise0.1347,5036,1755,747,271May 12 04:32 PM
Wang XiaodongChair, Scientific Advisory BrdMay 10Sale300.463,3941,019,7520May 12 04:32 PM
Wu XiaobinPresident, COO & GM ChinaMay 03Sale343.006,7152,303,2450May 05 04:46 PM
Huang JaneCMO, HematologyApr 29Option Exercise29.491,50044,2351,500May 03 04:35 PM
Huang JaneCMO, HematologyApr 29Sale354.921,500532,3870May 03 04:35 PM
Huang JaneCMO, HematologyMar 29Option Exercise29.491,50044,2351,500Mar 31 04:46 PM
Huang JaneCMO, HematologyMar 29Sale324.001,500485,9930Mar 31 04:46 PM
Huang JaneCMO, HematologyFeb 26Option Exercise29.491,50044,2351,500Mar 02 04:52 PM
Huang JaneCMO, HematologyFeb 26Sale320.731,500481,0990Mar 02 04:52 PM
Huang JaneCMO, HematologyJan 29Option Exercise29.491,50044,2351,500Feb 02 04:49 PM
Huang JaneCMO, HematologyJan 29Sale322.991,500484,4920Feb 02 04:49 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Option Exercise6.5012,60081,90012,600Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Sale344.9012,6004,345,6890Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Option Exercise6.501,4009,1001,400Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Sale344.471,400482,2560Jan 19 05:04 PM
BAKER BROS. ADVISORS LPDirectorJan 04Sale220.50121,15426,714,457968,943Jan 06 06:32 PM
Huang JaneCMO, HematologyDec 29Option Exercise29.491,50044,2351,500Dec 30 04:34 PM
Huang JaneCMO, HematologyDec 29Sale249.131,500373,6900Dec 30 04:34 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Option Exercise0.871,497,2001,300,0001,573,715Dec 16 04:43 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Sale229.0491,90021,048,4540Dec 16 04:43 PM
BAKER BROS. ADVISORS LPDirectorDec 04Sale220.501,511,546333,295,893979,003Dec 04 05:24 PM
Huang JaneCMO, HematologyNov 30Option Exercise29.491,50044,2351,500Dec 02 05:01 PM
Huang JaneCMO, HematologyNov 30Sale267.821,500401,7230Dec 02 05:01 PM
Huang JaneCMO, HematologyOct 29Option Exercise29.491,50044,2351,500Nov 02 04:44 PM
Huang JaneCMO, HematologyOct 29Sale300.061,500450,0930Nov 02 04:44 PM
Wang XiaodongChair, Scientific Advisory BrdOct 16Sale320.005,0001,600,0000Oct 20 04:44 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Option Exercise6.5014,00091,00014,000Oct 07 04:50 PM
Wang XiaodongChair, Scientific Advisory BrdOct 05Sale300.005,0001,500,0000Oct 07 04:56 PM
Wu XiaobinPresident & GM ChinaOct 05Sale300.004,0001,200,0000Oct 07 04:52 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Sale299.6014,0004,194,4130Oct 07 04:50 PM
Huang JaneCMO, HematologySep 29Option Exercise29.491,50044,2351,500Oct 01 04:52 PM
Huang JaneCMO, HematologySep 29Sale280.381,500420,5680Oct 01 04:52 PM
OYLER JOHNChief Executive OfficerSep 29Sale280.8223,3036,544,0300Sep 30 04:53 PM
OYLER JOHNChief Executive OfficerSep 28Sale280.0731,0008,682,0630Sep 30 04:53 PM
Wang XiaodongChair, Scientific Advisory BrdSep 25Sale280.425,0001,402,1160Sep 29 04:59 PM
Wu XiaobinPresident & GM ChinaSep 25Sale280.354,0001,121,4060Sep 29 04:57 PM
Wang XiaodongChair, Scientific Advisory BrdSep 17Sale260.275,0001,301,3560Sep 21 04:53 PM
Wu XiaobinPresident & GM ChinaSep 17Sale260.334,0001,041,3270Sep 21 04:50 PM
OYLER JOHNChief Executive OfficerSep 16Sale254.7727,2756,948,8070Sep 16 05:12 PM
OYLER JOHNChief Executive OfficerSep 15Sale254.2634,2148,699,3810Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Option Exercise6.5014,00091,00014,000Sep 16 05:10 PM
OYLER JOHNChief Executive OfficerSep 14Sale250.2519,7394,939,7820Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Sale250.2714,0003,503,7640Sep 16 05:10 PM
Huang JaneCMO, HematologySep 03Sale233.073,128729,0450Sep 08 04:44 PM
OYLER JOHNChief Executive OfficerSep 02Sale229.2227,8076,374,0240Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerSep 01Sale233.7920,2744,739,8090Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerAug 31Sale240.8612,9613,121,7650Sep 02 05:44 PM
Huang JaneCMO, HematologyAug 28Option Exercise29.493,00088,4703,000Sep 01 04:41 PM
Huang JaneCMO, HematologyAug 28Sale242.213,000726,6260Sep 01 04:41 PM
OYLER JOHNChief Executive OfficerAug 21Sale240.1940,7889,796,7750Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 20Sale234.6221,5235,049,7490Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 19Sale234.5629,8667,005,2650Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 14Sale211.158,7051,838,0340Aug 14 05:30 PM
OYLER JOHNChief Executive OfficerAug 13Sale214.4814,4433,097,7620Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Option Exercise31.592,89791,5162,897Aug 12 05:02 PM
OYLER JOHNChief Executive OfficerAug 12Sale212.1019,8204,203,7660Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Sale212.002,897614,1650Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Option Exercise31.591,90360,1161,903Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Sale213.041,903405,4090Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Option Exercise31.592,20069,4982,200Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Sale214.042,200470,8860Aug 12 05:02 PM
Wang XiaodongChair, Scientific Advisory BrdAug 10Sale211.064,000844,2290Aug 12 04:38 PM
OYLER JOHNChief Executive OfficerAug 05Sale223.2717,2543,852,2730Aug 05 05:43 PM